3-[[5-[2-[(3-chlorophenyl)amino]-6-methyl-4-pyrimidinyl]-3-pyridinyl]amino]-1-propanol | 405938-60-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-[[5-[2-[(3-chlorophenyl)amino]-6-methyl-4-pyrimidinyl]-3-pyridinyl]amino]-1-propanol
• 英文别名: 3-[[5-[2-(3-Chloroanilino)-6-methylpyrimidin-4-yl]pyridin-3-yl]amino]propan-1-ol
• CAS: 405938-60-5
• 化学式: C₁₉H₂₀ClN₅O
• 分子量: 369.854
• InChiKey: SDWYPQTVFNWBIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  83
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Pyrazine derivatives as modulators of tyrosine kinases
  申请人：——

  公开号：US20030060629A1

  公开（公告）日：2003-03-27

  The present invention provides pyrazine derivatives that inhibit tyrosine kinase activity. Certain pyrazine derivatives are selective inhibitors of vascular endothelial growth factor (VEGF) receptor tyrosine kinase. The present invention also provides pharmaceutical formulations containing the pyrazine derivatives and methods of use of these formulations as anti-tumor agents and to treat solid-tumor cancers, angiogenesis, diabetic retinopathy, rheumatoid arthritis, endometriosis and psoriasis.

  本发明提供了抑制酪氨酸激酶活性的吡嗪衍生物。某些吡嗪衍生物是选择性抑制血管内皮生长因子（VEGF）受体酪氨酸激酶的抑制剂。本发明还提供了含有这些吡嗪衍生物的制药配方以及将这些配方用作抗肿瘤剂和治疗实体瘤癌症、血管生成、糖尿病性视网膜病变、类风湿性关节炎、子宫内膜异位症和银屑病的方法。
• PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1330452A2

  公开（公告）日：2003-07-30
• US6710048B2
  申请人：——

  公开号：US6710048B2

  公开（公告）日：2004-03-23
• [EN] PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES<br/>[FR] DERIVES DE PYRAZINE TENANT LIEU DE MODULATEURS DE TYROSINE KINASE
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2002024681A2

  公开（公告）日：2002-03-28

  The present invention provides pyrazine derivatives that inhibit tyrosine kinase activity. Certain pyrazine derivatives are selective inhibitors of vascular endothelial growth factor (VEGF) receptor tyrosine kinase. The present invention also provides pharmaceutical formulations containing the pyrazine derivatives and methods of use of these formulations as anti-tumor agents and to treat solid-tumor cancers, angiogenesis, diabetic retinopathy, rheumatoid arthritis, endometriosis and psoriasis.